Nitric oxide, a potent vasodilator and an in hibitor of platelet aggregation, may be beneficial in the early stages of focal cerebral ischemia as it may facilitate collateral blood flow to the ischemic territory. Accord ingly, the effect of inhibition of nitric oxide synthesis on cerebral ischemic damage may vary depending on the timing of the inhibition relative to the induction of isch emia. We therefore studied the time course of the effect of nitric oxide synthesis inhibition on focal cerebral isch emic damage. The middle cerebral artery was perma nently occluded in spontaneously hypertensive rats and the nitric oxide synthase (NOS) inhibitor nitro-L-arginine methyl ester (L-NAME) was administered systemically (3 mg/kg) <5 min or 2, 3, or 6 h later. Arterial pressure, rectal temperature, plasma glucose, and hematocrit were monitored. Infarct volume was determined on thionin stained sections 24 h after induction of ischemia. NOS activity was determined in cerebellum from the conver sion of L-[3H]arginine to L-eHlcitrulline. Administration Nitric oxide (NO) is a molecular mediator that has been implicated in many physiological and pathological processes (see Bredt and Snyder, 1994, for review). Recent evidence indicates that NO par ticipates also in cerebral ischemic damage. How ever, some reports have suggested that NO is ben eficial to the ischemic brain, whereas other studies have provided evidence that NO is deleterious and may be a mediator of neurotoxicity (see Pelligrino,
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NO is a potent cerebral vasodilator and an inhib itor of platelet aggregation (Marshall et ai., 1988; Radomski et ai., 1991) . These "vascular" effects of NO could be beneficial to the ischemic tissue be cause they may increase CBF to oligemic regions and prevent microvascular occlusion by platelet ag gregates. This hypothesis is supported by studies showing that administration of the NO precursor L-arginine or of NO donors increases CBF to the ischemic brain and reduces the tissue damage pro duced by middle cerebral artery (MCA) occlusion (Buisson et ai., 1993b; Zhang and Iadecola, 19�3; Morikawa et ai., 1994; Zhang et ai., 1994a) . NO producing agents do not increase ischemic CBF or reduce infarct size when they are administered 2 h after induction of ischemia (Zhang and Iadecola, 1994 ), suggesting that the beneficial effects of NO occur only in the early phase of cerebral ischemia.
In the present study, we sought to investigate fur ther the role of NO in the initial stages of cerebral ischemia. We reasoned that if the protective effects of NO occur only in the early phase of cerebral ischemia, then inhibition of NO synthesis early af ter induction of ischemia should increase tissue damagf<. On the other hand, inhibition of NO syn thesis hours after induction of ischemia should not worsen tissue damage. To test this hypothesis, we administered the NO synthase (NOS) inhibitor ni tro-L-arginine methyl ester (L-NAME) at different times after occlusion of the rat MCA. The results indicate that NOS inhibitors can ameliorate or worsen ischemic damage depending on the timing of their administration relative to the induction of ce rebral ischemia.
METHODS
Methods for MCA occlusion, for determination of in farct size, and for measurement of NOS activity have been described in detail in previous publications (Zhang and ladecola, 1992 (Zhang and ladecola, -1994 (Zhang and ladecola, , ladecola et ai., 1994b Zhang et ai., 1994a) and will only be summarized. Studies were approved by the Animal Care and Use Committee of the University of Minnesota.
General surgical procedures
Studies were conducted on 37 male spontaneously hy pertensive rats (Harland) weighing 300-400 g. Spontane ously hypertensive rats were chosen because of the well known reliability of the size of ischemic lesions in this strain. Animals were not fasted. Anesthesia was induced with halothane (2-5% in 100% oxygen) administered through a facial mask. The left femoral artery was can nulated and rats were placed on a stereotaxic frame (Kopf). At this time, the halothane concentration was re duced to 1.0%. Body temperature was maintained at 37 ± O.soC by a thermostatically controlled infrared lamp con nected to a rectal probe. The femoral arterial catheter was connected to a pressure transducer for recording of arte rial pressure (AP) and heart rate. Plasma glucose was measured by a glucose analyzer (Beckman). Blood gases were not systematically measured because it was previ ously determined that arterial Peo 2 , Po 2 , and pH remain stable during procedures for MCA occlusion in spontane ously breathing rats (Zhang and ladecola, 1992) . After completion of the surgical procedures, the femoral arte rial catheter was tunneled under the skin and exteriorized at the level of the tail. The catheter was used for admin istration ofL-NAME, for recording of AP, and for deter mination of plasma glucose and hematocrit at different times after MCA occlusion.
Occlusion of MCA and measurement of infarct volumes
As described in detail elsewhere (Zhang and Iadecola, 1992 -1994 , Zhang et ai., 1994a a 3-to 4-mm hole was drilled at a site superior and lateral to the left foramen ovale to expose the distal portion of the left MCA. The J Cereb Blood Flow Metab, Vol. 15, No.4, 1995 MCA was elevated and cauterized medial to the inferior border of the inferior cerebral vein (Zhang et al., I 994a) . Wounds were infiltrated with lidocaine and sutured. Rats were allowed to recover and returned to their cages. Body temperature was monitored and maintained at 37°C until rats regained spontaneous movements, usually 30 min following discontinuation of anesthesia. The time of recovery from anesthesia was uniform in the groups of rats studied. Twenty-four hours after MCA occlusion, rats were killed and their brains were removed. The fore brain was separated from the hindbrain and frozen in cooled isopentane (-30°C). Coronal sections (thickness 30 fLm) were serially cut in a cryostat, collected at 300-fLm intervals, and stained with thionin. Infarct volume was determined using an image analyzer (MCID; Imaging Re search) as previously described (Zhang and ladecola, 1992) .
NOS assay
Methods for measuring brain NOS catalytic activity us ing the assay of Bredt and Snyder (1994) have been de scribed in detail elsewhere (Iadecola et al., 1994b) and are briefly summarized. After removing the brain from the skull, the cerebellum was separated from the hindbrain and frozen in liquid nitrogen. Systemic administration of L-NAME results in comparable NOS inhibition in cere bellum and forebrain (S. Xu and C. Iadecola, unpublished observations). For NOS assay, samples were homoge nized in 20 mM N-2-hydroxyethylpiperazine-N'-2ethanesulfonic acid (HEPES) containing 0.5 mM eth yleneglycol-bis-(I3-aminoethyl ether)-N,N,N' ,N' tetraacetate (EGTA), I mM dithiothreitol, and 0.32 M sucrose at 23,000 rpm for 30 s (Polytron/PT3000; Brink mann). The homogenate was then centrifuged at 20,000 g for 15 min, and the supernatant was applied to I-ml col umns of Dowex AG50W-X8 (Na + form) to remove en dogenous arginine. Triplicates of aliquots of the cytosol (150 fLg protein) were incubated for 45 min (37°C) with a buffer containing 20 mM HEPES, 0.5 mM EGTA, 1 mM dithiothreitol, 0.32 M sucrose, 0.5 mM Ca 2 + (l fLM free Ca 2 +), 200 fLM NADPH, 1 fLM L-arginine, and I fLCi/ml L-eH]arginine. The reaction was stopped by adding 2 ml of 20 mM HEPES containing 2 mM ethylenediaminetet raacetate (pH 5.5). Samples were applied to Dowex AG50W-X8 (Na + form) columns to remove L-[3H] arginine. Columns were then washed with 2 ml of wa ter and L-[3Hlcitrulline was quantified in the flow-through fraction using a liquid scintillation spectrophotometer (Beckman LS 6000). The level of L-eH]citrulline was computed after subtracting the blank value that repre sents nonspecific radioactivity in the absence of enzyme activity (usually 800-1000 dpm). Samples from saline treated rats were assayed together with samples of ani mals treated with L-NAME. Enzyme activity was ex pressed as disintegrations per minute per 150 fLg protein per 45 min.
Experimental protocol
The MCA was occluded as described. L-NAME (3 mgl kg; Sigma, St. Louis, MO, U.S.A.) was dissolved in nor mal saline and administered through the femoral arterial catheter <5 min (n = 6) and 2 (n = 6), 3 (n = 10); or 6 h (n = 8) after MCA occlusion. The rationale for adminis tering L-NAME at 2, 3, and 6 h after MCA occlusion was to study the consequences of NOS inhibition at a time when the vascular effects of NO were no longer likely to affect infarct size (Zhang and Iadecola, 1994) . In rats in which L-NAME was administered <5 min after MCA oc clusion (n = 6), the drug was injected while the animals were still under anesthesia. In the group of rats receiving vehicle, saline was injected intraarterially <5 min (n = 1) or 2 (n = 2), 3 (n = 2), and 6 h (n = 2) after MCA occlusion. Rats were randomly assigned to each group. In all groups, AP, rectal temperature, and plasma glucose were measured before L-NAME administration and 1, 3, and 6 h after. AP, temperature, and glucose were also measured 12 and 24 h after MCA occlusion. Arterial he matocrit was measured before injection and 12 and 24 h after MCA occlusion. Twenty-four hours after MCA oc clusion, rats were killed for determination of infarct size (Zhang and Iadecola, 1992) and for measurement of cere bellar NOS activity (Iadecola et aI., 1994b) .
We initially planned to study both "low" (3 mg/kg) and "high" (20--4 0 mg/kg) doses of L-NAME. However, we found that spontaneously hypertensive rats treated with high doses of L-NAME after MCA occlusion developed marked hypertension and arrhythmias. These rats died 2-4 h later, presumably because of cardiac insufficiency. High mortality was also observed in Sprague-Dawley rats treated with 20--40 mg/kg of L-NAME after MCA occlu sion. Therefore, we elected to use a low dose of L-NAME. Interestingly, in a previous study, we did not observe deaths in Sprague-Dawley rats treated with 20-40 mg/kg of L-NAME but not subjected to MCA occlu sion (Iadecola et a\., 1994b) .
Data analysis
Data presented in the text, tables, and figures are ex pressed as means ± SD. Comparisons among multiple groups were statistically evaluated by the analysis of vari ance and the Tukey-Kramer modification of Tukey's test (Systat, Inc.). Differences were considered significant at p < 0.05.
RESULTS
Effects of L-NAME on AP, hematocrit, plasma glucose, and body temperature AP, hematocrit, plasma glucose, and rectal tem perature of the groups of rats studied are presented in Table 1 . In rats injected with vehicle (saline, n = 7), these parameters remained stable over time (p > 0.05, analysis of variance and Tukey's test). L-NAME tended to increase AP 1, 3, and 6 h after administration. However, in agreement with previ ous reports using comparable doses of L-NAME (Ashwal et ai., 1993; Buisson et ai. , 1993a) , the ef fect was small and did not reach statistical signifi cance (p > 0.05). In rats in which L-NAME was administered <5 min after MeA occlusion, AP was lower and plasma glucose was higher than in the 156 ± 13 37.9 ± 0.5 148 ± 10 50 ± I 143 ± 18 37.9 ± 0.2 149 ± 14 50 ± 2 8
Means ± SD. AP, arterial pressure; Ht, hematocrit; MCAO, middle cerebral artery occlusion; L-NAME, nitro-L-arginine methyl ester; Temp., rectal temperature . a Data at 3 h after L-NAME administration were not acquired. b Rats under anesthesia, p < 0.05 from other time points (analysis of variance and Tukey's test).
other groups (p < 0.05, n = 6). This is probably due to the fact that in this particular group of rats, plasma glucose was determined while animals were still under the influence of anesthesia. Otherwise, plasma glucose, hematocrit, and rectal temperature did not differ among groups at the time point stud ied (p > 0.05).
Effect of L-NAME on volume of infarct produced by
MCA occlusion
In rats treated with vehicle (n = 7), distal MCA occlusion produced an infarct that involved mainly the neocortex (Table 2) , a finding in agreement with previous reports from this and other laboratories (Yamamoto et al., 1992; Morikawa et al., 1994; Zhang et al., 1994a; Zhang and Iadecola, 1994) . Ad ministration of L-NAME <5 min after MCA occlu sion (n = 6) increased the size of the total infarct by 23 ± 14% (mean ± SD, p < 0.05, from saline), whereas administration of L-NAME 2 h after MeA occlusion (n = 6) did not affect infarct size (p > 0.05) ( Table 2) . Interestingly, when L-NAME was administered 3 h after MeA occlusion (n = 10), the size of the total infarct was smaller ( -11 ± 13%), an effect that was statistically significant only for the cerebral cortex ( -14 ± 11 %; p < 0.05). Admin istration of L-NAME 6 h after MeA occlusion (n = 8) did not affect infarct size (p > 0.05).
Effect of L-NAME on NOS activity
The effect ofL-NAME administration on cerebel lar NOS catalytic activity, assayed 24 h after MeA occlusion, is illustrated in Fig. 1 . L-NAME reduced cerebellar NOS activity, an effect that was statisti cally significant at 2,3, and 6 h after MeA occlusion (p < 0.05 from saline). The reductions in NOS ac tivity, which ranged from 16 to 25%, did not dif fer among the groups of rats treated with L-NAME (p > 0.05). (NOS) enzymatic activity in the cerebellum. NOS activity was assayed in cerebellar cell lysate using the isotopic conver sion assay of Bredt and Snyder (1994) . L-NAME reduced NOS activity by 16-25%. Differences in NOS activity were statisti cally different from those of saline-injected rats at 2, 3, and 6 h after middle cerebral artery (MeA) occlusion (p < 0.05 from saline, analysis of variance and Tukey's test).
DISCUSSION
We have demonstrated that the NOS inhibitor L-NAME increases the infarct produced by perma nent MeA occlusion when administered immedi ately after induction of ischemia. In contrast, ad ministration of L-NAME at later times after MeA occlusion either reduces or does not affect stroke size. Therefore, L-NAME can either increase or de crease infarct size depending on the timing of its administration relative to the induction of ischemia.
The time dependence of the effect of L-NAME on permanent focal cerebral ischemia is not a conse quence of variation in AP, hematocrit, or body tem perature, because these parameters were monitored and did not differ among the groups of rats studied. Similarly, after recovery from anesthesia, plasma glucose was comparable in all groups. Furthermore, the changes in infarct size observed with the differ ent timing of administration of L-NAME cannot be accounted for by variations in the degree of brain NOS inhibition because NOS activity in the cere bellum was comparably reduced in all groups. It is also unlikely that the effect of L-NAME on infarct size, at the doses used in the present study, is due to its purp o rted ability to inhibit muscarinic receptors (Buxton et al., 1993) because (a) atropine-like ef fects are seen in vitro at relatively high concentra tion of L-NAME (Buxton et al., 1993) ; (b) the in crease in infarct size associated with L-NAME ad ministration is comparable with that reported with administration of nitro-L-arginine (Yamamoto et al., 1992) , a NOS inhibitor that does not have antimus carinic effects (Buxton et al., 1993) ; and (c) the muscarinic cholinergic antagonist atropine does not affect infarct size in focal cerebral ischemia (Reis et al., 1991) .
Although there is evidence that NO is involved in cerebral ischemic damage, the role that NO plays in the mechanisms of cerebral ischemia remains to be defined (see Pelligrino, 1993; Iadecola et al., 1994a, for review) . Thus, some studies have suggested that NO ameliorates focal cerebral ischemic damage (Yamamoto et al., 1992; Zhang and Iadecola, 1993) , whereas other investigations have provided evi dence to the contrary (Nowicki et al., 1991; Na gafuji et al., 1992; Buisson et al., 1993a) . The bio logical characteristics of NO suggest that this agent could be both beneficial and deleterious to the isch emic brain. On the one hand, NO is a potent va sodilator and an inhibitor of platelet aggregation (Marshall et al., 1988; Radomski et al., 1991) and, as such, could increase CBF to regions of oligemia and prevent microvascular plugging by activated plate lets. These effects would improve collateral flow and reduce ischemic damage. NO can also be neu roprotective by inhibiting calcium fluxes through N methyl-D-aspartate receptors and by scavenging free radicals (Lipton et al., 1993; Wink et al., 1993) . On the other hand, NO is cytotoxic because it leads to inhibition of glycolytic and respiratory chain en zymes while inducing DNA breakdown and gener ating toxic free radicals (see Stamler, 1994 , for re view). Furthermore, NO leads to activation of poly (ADP-ribose) synthetase, which may also contribute to neurotoxicity . The toxic effects of NO could aggravate the meta bolic state of the ischemic brain, thereby worsening tissue damage (Pelligrino, 1993) .
Studies from this and other laboratories suggest that the vascular actions of NO are beneficial in focal cerebral ischemia. Administration of NO generating agents or of the NO precursor L-arginine increases intraischemic blood flow and reduces the size of the infarct resulting from MCA occlusion (Buisson et al., 1993b; Zhang and Iadecola, 1993; Dalkara et al., 1994; Morikawa et al., 1994; Zhang et al., 1994a) . NO donors lose their efficacy when they are administered > 1 h after MCA occlusion (Zhang and Iadecola, 1994) . The present study shows that L-NAME increases ischemic damage when given immediately after induction of isch emia. If L-NAME is administered ;;:: 2 h after MCA occlusion, the size of the infarct is either unchanged or slightly reduced. Although the mechanisms re sponsible for these effects of L-NAME have not been elucidated, one possibility is that inhibition of NO synthesis worsens ischemic damage by reduc ing CBF and promoting the infarction of penumbral regions. In support of this hypothesis is the finding that L-NAME reduces blood flow in the border zone of the infarct after MCA occlusion . According to this interpretation, the data with NOS inhibitors agree with the results obtained using NO donors and suggest that NO pro duction is beneficial in the early stages of cerebral ischemic damage because it increases intraischemic CBF. However, the possibility that NO reduces ischemi c damage by conversion to nitrosonium and inhibition of N-methyl-D-aspartate receptors (Lip ton et al., 1993) or by scavenging free radicals (Wink et al., 1993) cannot be entirely ruled out on the basis of the present study.
Of interest is the observation that L-NAME re duces, albeit slightly, the size of the infarct when it is administered 3 h after MCA occlusion. Although this finding supports the contention that the cyto toxic actions of NO can be deleterious to the isch emic brain, it also indicates that the role of NO in cerebral ischemia is multifaceted. Thus, NO can be protective or destructive depending on the stage of development of cerebral ischemic damage (see next paragraph). Recent experiments in knock-out mice lacking neuronal NOS or using the relatively selective neuronal NOS inhibitor 7-ni troindazole have provided ev idence that neuronal NO contributes to focal cere bral ischemic damage. It is therefore conceivable that the protective effect observed when L-NAME was administered 3 h after MCA occlusion reflects inhibition of neuronal NOS. However, it remains to be established why the infarct size was not signifi cantly reduced when L-NAME was administen ! d 6 h after MCA occlusion. Further studies will be re quired to elucidate the time dependence of the ef fects of NO in permanent focal ischemia.
The available evidence suggests the following hy pothetical sequence of events regarding the effect of nonselective NOS inhibitors, i.e., agents that in hibit all isoforms of NOS indiscriminately, on tissue outcome in focal cerebral ischemia. In the immedi ate phase after arterial occlusion, the vascular ef fects of NO are beneficial to the ischemic tissue as they increase collateral flow and decrease the se verity of the ischemic insult in marginally perfused brain tissue at risk for infarction (Zhang and Iade cola, 1993; Dalkara et aI., 1994; Morikawa et aI., 1994; Zhang et aI., 1994a) . Inhibition of NO produc tion at this initial stage results in enlargement of the ischemic lesion because the "protective" vascular effects of NO outweigh the "destructive" paren chymal effects (Yamamoto et aI., 1992; Zhang and Iadecola, 1993) . After the first hour of ischemia, the vascular actions of NO are no longer beneficial to the tissue Zhang and Iadecola, 1994) . At this stage, inhibition of NO synthesis pro tects the tissue from infarction because the toxic effects of NO, probably parenchymal in origin, pre dominate. After the first day of ischemia, expres sion of the inducible isoform of NOS occurs in non neuronal cells (Iadecola et aI., 1995b) . This isoform of NOS produces NO in large amounts and contin uously and may contribute to the late stages of tis sue damage. Thus, inhibition of NOS at this time is also protective (Iadecola et aI., 1995a) . It is there fore not surprising that reports on the effect of non selective NOS inhibition in cerebral ischemia have been conflicting because in these studies the timing of administration of NOS inhibitors relative to the induction of ischemia and the dosage have varied widely (e.g., Nowicki et aI., 1991; Nagafuji et aI., 1992; Yamamoto et ai., 1992; Buisson et ai., 1993a; Zhang and Iadecola, 1993) . For example, studies of permanent focal ischemia showing the greatest pro tection by NOS inhibition have used multiple ad ministration of NOS inhibitors over several days (Nowicki et aI., 1991; Buisson et aI., 1992; Nagafuji et ai., 1992; Carreau et aI., 1994) , whereas studies in which NOS inhibitors were administered for a brief period after MCA occlusion have generally re ported worsening of damage (Yamamoto et aI., 1992; Zhang and Iadecola, 1993) . It is, however, important to point out that other factors related to the experimental models employed are also likely to play a role in the controversy (see Iadecola et ai., 1994a, for review) .
The sources of NO responsible for the mainte nance of intraischemic CBF early after induction of ischemia have not been clearly defined. In the nor mal brain, NO is produced by "constitutive," cal cium-dependent isoforms of NOS present in endo-J Cereb Blood Flow Metab, Vol. 15, No.4, 1995 thelial cells, selected neurons, perivascular nerves, and possibly astroglia (Bredt et aI., 1990; Iadecola et aI., 1993; Murphy et aI., 1993) . After focal cere bral ischemia, NO is also produced by nonneuronal cells invading the area of infarction (Iadecola et ai., 1995b) . The enzyme responsible for NO production after focal ischemia is the calcium-independent, "inducible" isoform of NOS (iN OS) (Iadecola et aI., 1995b) . Because L-NAME inhibits both of these NOS isoforms, it cannot be established whether the observed effects result from inhibition of iNOS or calcium-dependent NOS. However, inhibition of iNOS by L-NAME can be virtually ruled out be cause iNOS enzyme activity develops >24 h after focal ischemia (Iadecola et aI., 1995b) , and in the present study rats were not allowed to survive >24 h after MCA occlusion. It is therefore likely that the target of L-NAME is calcium-dependent NOS. Be cause L-NAME was administered systemically, it can be expected that calcium-dependent NOS in brain was inhibited in neurons, perivascular auto nomic nerve fibers, and endothelial cells. Transec tion of the perivascular nerve fibers arising from the sphenopalatine ganglia, which contain NOS (Iade cola et ai., 1993), enlarges the infarct associated with MCA occlusion (Kano et aI., 1991) . Thus, one of the sources of NO after ischemia is likely to be in perivascular nerves. However, it is conceivable that the NO responsible for maintaining CBF in the area of ischemia originates also from other sources, presumably NOS neurons and endothelial cells.
In conclusion, we have demonstrated that the ef fects of inhibition of NO synthesis on focal cerebral ischemic damage are time dependent. Thus, inhibi tion of NO synthesis worsens ischemic damage when instituted shortly after induction of ischemia, and it does not affect or reduces damage at later times. The results support the hypothesis that the vascular actions of NO are beneficial in the early stages of permanent focal cerebral ischemia.
